A case of non-alcoholic fatty liver disease (NAFLD) aggravated after treatment with raloxifene

Journal of Japanese Society of Gastroenterology

Volumn 108, Issue 12, 2011, Pages 2036-2041

  Matsumura, Makiko ^a   Tashiro, Koichi ^a   Miura, Akihiro ^a   Tajima, Takehiro ^a   Kinoshita, Ikuharu ^a   Kojima, Eigo ^a   Yoshizawa, Akihiko ^a  

^a Nagano Chuo Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FUNCTION TEST; MEDICAL HISTORY; NONALCOHOLIC FATTY LIVER; OSTEOPOROSIS; SIDE EFFECT;

AGED; FATTY LIVER; FEMALE; HUMANS; OSTEOPOROSIS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84455163163     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kleiner DE, Brunt EM, Van Natta M, et al : Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 ; 1313-1321 : 2005
2. Brunt EM, Janney CG, Di Bisceglie AM, et al : Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 ; 2467-2474 : 1999
3. Ogawa Y, Murata Y, Nishioka A, et al : Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 351 ; 725 : 1998
4. Nemoto Y, Toda K, Ono M, et al : Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest 105 ; 1819-1825 : 2000
5. Murata Y, Ogawa Y, Saibara T, et al : Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7 ; 1299-1304 : 2000
6. Coskun U, Törüner FB, Günel N : Tamoxifen therapy and hepatic steatosis. Neoplasma 49 ; 61-64 : 2002
7. Nishino M, Hayakawa K, Nakamura Y, et al : Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer : high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol 180 ; 129-134 : 2003
8. Nemoto Y, Saibara T, Ogawa Y, et al : Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Intern Med 41 ; 345-350 : 2002
9. Takamura T, Shimizu A, Komura T, et al : Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis. Intern Med 46 ; 579-581 : 2007
10. Ettinger B, Black DM, Mitlak BH, et al : Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282; 637-645 : 1999
11. Delmas PD, Ensrud KE, Adachi JD, et al : Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis : four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 ; 3609-3617 : 2002
12. Cauley JA, Norton L, Lippman ME, et al : Continued breast cancer risk reduction in postmenopausal women treated with raloxifene : 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 ; 125-134 : 2001
13. Seki K, Minami Y, Nishikawa M, et al : "Non alcoholic steatohepatitis" induced by massive doses of synthetic estrogen. Gastroenterol Jpn 18 ; 197-203 : 1983
14. Farrell GC : Drugs and steatohepatitis. Semin Liver Dis 22 ; 185-194 : 2002
15. Ricci C, Longo R, Gioulis E, et al : Non-invasive in vivo quantitative assessment of fat content in human liver. J Hepatol 27 ; 108-113 : 1997